FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

						_	`												
1. Name and Address of Reporting Person* HANLON SUSAN M						2. Issuer Name and Ticker or Trading Symbol HAEMONETICS CORP [HAE]								Checl	ationship of all applica Director Officer (r 10% Owner			vner
(Last) (First) (Middle) 400 WOOD ROAD						3. Date of Earliest Transaction (Month/Day/Year) 10/25/2013									X below) below) VP Finance				
(Street)						4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)					
BRAINTREE MA 02184														X	Form filed by One Reporting Person Form filed by More than One Reporting				
(City) (State) (Zip)															Person				9
		Tab	le I - No	on-Deri	vativ	e S	ecurit	ies A	cquired	l, Di	sposed of	, or Ben	eficia	ally	Owned				
Date					2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)			Acquired (A) or (D) (Instr. 3, 4 and				s lly	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)
								Code	v	Amount	(A) or (D)	Price		Transaction(s) (Instr. 3 and 4)				,	
Common S	Stock			10/25	10/25/2013				D		149(1)	D	\$41.09		18,582			D	
Common S	Stock			10/25/2013					D		195(1)	D	\$39.5518		18,387		D		
Common Stock					10/28/2013				D		217(1)	D	\$39.5516		18,170			D	
Common Stock 10					/2013				D		77 ⁽¹⁾	D	\$39.5508		18,093			D	
		-	Table II								posed of, o				wned				
1. Title of Derivative Security (Instr. 3)	erivative Conversion Date Execution or Exercise (Month/Day/Year) if any		ned n Date,	4. Transa	ansaction		5. Number 6		6. Date Exercisab Expiration Date (Month/Day/Year)		able and 7. Title and of Securitie		unt	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securitie Beneficia Owned Following Reported Transact (Instr. 4)	e s ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code V		(A)	(D)	Date Exercisable		Expiration Date	Title	Amor or Numl of Share	ber					
Non- Qualified Stock Option (right to buy)	\$25.535								10/24/200)8 ⁽²⁾	10/24/2014	Common Stock	7,1	38		7,13	8	D	
Non- Qualified Stock Option (right to buy)	\$26.47								10/27/201	.0 ⁽²⁾	10/27/2016	Common Stock	14,6	590		14,69	00	D	
Non- Qualified Stock Option (right to buy)	\$27.275								10/22/200	₉ 9 ⁽²⁾	10/22/2015	Common Stock	7,20	06		7,20	6	D	
Non- Qualified Stock Option (right to buy)	\$27.495								10/27/201	.1 ⁽²⁾	10/27/2017	Common Stock	22,3	348		22,34	18	D	
Non- Qualified Stock Option (right to buy)	\$30.67								10/25/201	.2 ⁽²⁾	10/25/2018	Common Stock	20,7	'26		20,72	26	D	
Non- Qualified Stock Option (right to buy)	\$39.055								10/24/201	.3 ⁽²⁾	10/24/2019	Common Stock	16,8	182		16,88	32	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Non- Qualified Stock Option (right to buy)	\$41.66							10/23/2014 ⁽²⁾	10/23/2023	Common Stock	18,456		18,456	D	
Performance Shares	\$0.0							03/31/2017 ⁽³⁾	12/31/2017 ⁽³⁾	Common Stock	12,500		12,500	D	

Explanation of Responses:

- 1. Pursuant to a 10b5-1 Plan to cover tax liability for released shares.
- 2. Grant to reporting person of right to buy shares of common stock exercisable in annual increments of 25 percent beginning on the first anniversary of the date of grant.
- 3. Market Share Units represent a right to receive one share of Haemonetics Corporation common stock for each Market Stock Unit based on Haemonetics stock price during the 30 trading days prior to March 31, 2017. The number of Market Stock Units (and therefore the number of shares payable) will depend on the Companys stock price during such period. The Market Stock Units disclosed in column 5 represent a target amount. The number of shares ultimately issued could range from none to three times the target amount in column 5. The Market Stock Units were granted under the 2005 Haemonetics Corporation Long-Term Incentive Compensation Plan and are exempt under Rule 16b-3(d).

By: Alexander Steffan For: 10/29/2013 Susan Hanlon

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.